Target Price | €28.56 |
Price | €27.50 |
Potential | 3.85% |
Number of Estimates | 24 |
24 Analysts have issued a price target Bayer 2026 . The average Bayer target price is €28.56. This is 3.85% higher than the current stock price. The highest price target is €36.75 33.64% , the lowest is €23.23 15.53% . | |
A rating was issued by 28 analysts: 12 Analysts recommend Bayer to buy, 15 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Bayer stock has an average upside potential 2026 of 3.85% . Most analysts recommend the Bayer stock at Hold. |
24 Analysts have issued a sales forecast Bayer 2025 . The average Bayer sales estimate is €46.7b . This is 1.16% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €48.8b 5.78% , the lowest is €44.2b 4.31% .
This results in the following potential growth metrics:
2024 | €46.6b | 2.16% |
---|---|---|
2025 | €46.7b | 0.22% |
2026 | €47.2b | 1.01% |
2027 | €48.3b | 2.29% |
2028 | €49.6b | 2.76% |
2029 | €50.2b | 1.13% |
2030 | €51.9b | 3.43% |
2031 | €50.3b | 3.09% |
2032 | €50.9b | 1.32% |
23 Analysts have issued an Bayer EBITDA forecast 2025. The average Bayer EBITDA estimate is €9.5b . This is 43.23% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €11.6b 74.50% , the lowest is €7.9b 19.19% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €12.8b | 30.71% |
---|---|---|
2025 | €9.5b | 25.77% |
2026 | €9.9b | 4.46% |
2027 | €10.3b | 4.30% |
2028 | €9.8b | 5.43% |
2029 | €9.7b | 0.79% |
2024 | 27.42% | 29.18% |
---|---|---|
2025 | 20.31% | 25.93% |
2026 | 21.00% | 3.40% |
2027 | 21.41% | 1.95% |
2028 | 19.71% | 7.94% |
2029 | 19.33% | 1.93% |
23 Bayer Analysts have issued a net profit forecast 2025. The average Bayer net profit estimate is €4.6b . This is 235.75% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €5.3b 256.12% , the lowest is €4.1b 219.99% .
This results in the following potential growth metrics and future Net Margins:
2024 | €-2.6b | 13.23% |
---|---|---|
2025 | €4.6b | 281.82% |
2026 | €4.8b | 3.66% |
2027 | €5.3b | 9.66% |
2028 | €5.7b | 8.10% |
2029 | €5.8b | 1.12% |
2030 | €6.4b | 10.92% |
2024 | -5.48% | 11.31% |
---|---|---|
2025 | 9.93% | 281.35% |
2026 | 10.19% | 2.62% |
2027 | 10.93% | 7.26% |
2028 | 11.50% | 5.22% |
2029 | 11.50% | 0.00% |
2030 | 12.33% | 7.22% |
23 Analysts have issued a Bayer forecast for earnings per share. The average Bayer EPS is €4.72 . This is 235.63% higher than earnings per share in the financial year 2024. The highest EPS forecast is €5.43 256.03% , the lowest is €4.17 219.83% .
This results in the following potential growth metrics and future valuations:
2024 | €-2.60 | 13.04% |
---|---|---|
2025 | €4.72 | 281.54% |
2026 | €4.90 | 3.81% |
2027 | €5.37 | 9.59% |
2028 | €5.80 | 8.01% |
2029 | €5.87 | 1.21% |
2030 | €6.51 | 10.90% |
2031 | €4.70 | 27.80% |
2032 | €4.86 | 3.40% |
Current | -7.90 | 62.22% |
---|---|---|
2025 | 5.82 | 173.65% |
2026 | 5.62 | 3.44% |
2027 | 5.12 | 8.90% |
2028 | 4.74 | 7.42% |
2029 | 4.69 | 1.05% |
2030 | 4.22 | 10.02% |
Based on analysts' sales estimates for 2025, the Bayer stock is valued at an EV/Sales of 1.28 and an P/S ratio of 0.58 .
This results in the following potential growth metrics and future valuations:
Current | 1.30 | 2.99% |
---|---|---|
2025 | 1.28 | 1.19% |
2026 | 1.27 | 1.00% |
2027 | 1.24 | 2.24% |
2028 | 1.21 | 2.69% |
2029 | 1.20 | 1.12% |
2030 | 1.16 | 3.31% |
2031 | 1.19 | 3.19% |
2032 | 1.18 | 1.31% |
Current | 0.59 | 4.19% |
---|---|---|
2025 | 0.58 | 1.16% |
2026 | 0.57 | 1.00% |
2027 | 0.56 | 2.23% |
2028 | 0.55 | 2.69% |
2029 | 0.54 | 1.12% |
2030 | 0.52 | 3.30% |
2031 | 0.54 | 3.18% |
2032 | 0.53 | 1.30% |
Analyst | Rating | Action | Date |
---|---|---|---|
BERENBERG |
Hold
➜
Hold
|
Unchanged | Sep 11 2025 |
LANDESBANK BADEN-WUERTTEMBERG |
Hold
➜
Hold
|
Unchanged | Aug 29 2025 |
HSBC GLOBAL INVESTMENT RESEARCH |
Buy
➜
Buy
|
Unchanged | Aug 25 2025 |
JEFFERIES |
Hold
➜
Hold
|
Unchanged | Aug 18 2025 |
SOLVENTIS RESEARCH |
Buy
➜
Buy
|
Unchanged | Aug 13 2025 |
ROTHSCHILD & CO REDBURN |
Neutral
➜
Neutral
|
Unchanged | Aug 13 2025 |
DZ BANK |
Buy
➜
Buy
|
Unchanged | Aug 12 2025 |
Analyst Rating | Date |
---|---|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Sep 11 2025 |
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Hold
➜
Hold
|
Aug 29 2025 |
Unchanged
HSBC GLOBAL INVESTMENT RESEARCH:
Buy
➜
Buy
|
Aug 25 2025 |
Unchanged
JEFFERIES:
Hold
➜
Hold
|
Aug 18 2025 |
Unchanged
SOLVENTIS RESEARCH:
Buy
➜
Buy
|
Aug 13 2025 |
Unchanged
ROTHSCHILD & CO REDBURN:
Neutral
➜
Neutral
|
Aug 13 2025 |
Unchanged
DZ BANK:
Buy
➜
Buy
|
Aug 12 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.